NSW Premier Gladys Beerjiklian restates, in stronger terms, her lack of confidence in her own AZ vaccine: Even more reasons why Vaccitech share price is likely to remain below IPO price

 by Ganesh Sahathevan 

This latest and stronger  condemnation of the AstraZeneca vaccine (Vaccitech), coincides with Dame Professor Sarah Gilbert's attempts to promote and defend her vaccine in Australia (see below).

TO BE READ WITH 

Thursday, September 9, 2021

AZ vaccine designer Dame Prof Sarah Gilbert 's Vaccitech share price continues to flounder despite Gilbert warning Australians that they will die if unvaccinated: Taxpayers paying for her vaccine should treat her product and claims with the same scepticism as investors

 by Ganesh Sahathevan 

Dame Professor Sarah Gilbert's Vaccitech share price has a had a torrid day ,despite her Australian media blitz:

As reported on this blog (see below), Vaccitech's IPO flopped, and the company continues to trade below its IPO price of USD 17. This is despite its COVID vaccine story and its backers which include Google, TenCent, and Sequoia. The market is clearly not impressed with Vaccitech's potential, despite its COVID story. Taxpayers who are paying for the  AZ COVID  vaccine ought to be equally sceptical. 

TO BE READ WITH 

Wednesday, September 8, 2021

AstraZeneca COVID vaccine designer Prof Sarah Gilbert warns the unvaccinated that they will die; meanwhile her vaccine company's share price flopped at IPO, continues to flounder

 by Ganesh Sahathevan 

Prof Sarah Gilbert owns 5.2% of Vaccitech, according to filings at Companies House. If the firm achieved a flotation value of £425m, her stake would be worth £22m. Photograph: John Cairns/University of Oxford/PA

The Guardian reported in April 2021:

Prof Sarah Gilbert, the scientist who led the team that created the Oxford/AstraZeneca coronavirus vaccine, is set for a payday of more than £20m as the biotech firm she co-founded prepares to float on the stock market in the US.

Gilbert, who became a household name as a result of her work creating Oxford’s Covid-19 vaccine, owns 5.2% of Vaccitech, a Oxford University spin-out company that owns the biotechnology behind the AstraZeneca vaccine and others for Mers, hepatitis B, the virus that causes shingles, and a range of cancers.

The IPO document filed at the SEC does not disclose  any sale of shares by existing shareholders,  only fund raising. 

Vaccitech shares were offered at USD 17 per  share (or technically, per American Depository Receipt).  The IPO and subsequent NASDAQ float has not gone well.  The company continues to trade below its IPO price.

Meanwhile Gilbert has given an interview on Australian TV in which she has warned the unvaccinated of the dire consequences of not using her product: 

So it's really important that people look at the whole picture. With the Delta variant, which is spreading so rapidly, it's going to reach everybody who is not vaccinated and also reach those people who are vaccinated and even if they then get infected, they tend to have a much milder disease. They are protected against hospitalisation.

So really we can't hide from this virus any more. Initial plans were to try to eliminate the virus. That's not going to be possible with the versions that we have spreading now. We have to be prepared to meet it and to deal with it, and that means vaccination.

END